Search research articles
Contact Us
Filters
Showing results (71-80 of 86) with videos related to
Page
of 9
Sort By:
JCO Precision Oncology
|
April 9, 2024
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E
Monica F Chen, Zihe Song, Helena A Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Young K Chae, Fangxin Hong, Christos Vaklavas, et al.
JCO Precision Oncology
|
January 18, 2023
High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer
Inna Chervoneva, Amy R Peck, Yunguang Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J
Roisin M Connolly, Victoria Wang, David M Hyman, et al.
JCO Precision Oncology
|
August 8, 2022
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B
Philippe L Bedard, Shuli Li, Kari B Wisinski, et al.
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1
Jun Gong, Alain C Mita, Zihan Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2019
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study
Nilofer S Azad, Robert J Gray, Michael J Overman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2023
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
Amy S Clark, Fangxin Hong, Richard S Finn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2020
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
Keith T Flaherty, Robert J Gray, Alice P Chen, et al.
JCO Precision Oncology
|
April 13, 2023
Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
Kari B Wisinski, Yael Flamand, Melissa A Wilson, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 86) with videos related to
Sort By:
Page
of 9
JCO Precision Oncology
|
April 9, 2024
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E
Monica F Chen, Zihe Song, Helena A Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Young K Chae, Fangxin Hong, Christos Vaklavas, et al.
JCO Precision Oncology
|
January 18, 2023
High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer
Inna Chervoneva, Amy R Peck, Yunguang Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J
Roisin M Connolly, Victoria Wang, David M Hyman, et al.
JCO Precision Oncology
|
August 8, 2022
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B
Philippe L Bedard, Shuli Li, Kari B Wisinski, et al.
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1
Jun Gong, Alain C Mita, Zihan Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2019
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study
Nilofer S Azad, Robert J Gray, Michael J Overman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2023
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
Amy S Clark, Fangxin Hong, Richard S Finn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2020
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
Keith T Flaherty, Robert J Gray, Alice P Chen, et al.
JCO Precision Oncology
|
April 13, 2023
Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
Kari B Wisinski, Yael Flamand, Melissa A Wilson, et al.
Page
of 9